Previous work with respect to the treatments and relapse time for breast cancer patients is extended by applying a Markov chain to model three different types of breast cancer patients: alive without ever having relapse, alive with relapse, and deceased. It is shown that combined treatment of tamoxifen and radiation is more effective than single treatment of tamoxifen in preventing the recurrence of breast cancer. However, if the patient has already relapsed from breast cancer, single treatment of tamoxifen would be more appropriate with respect to survival time after relapse. Transition probabilities between three stages during different time periods, 2-year, 4-year, 5-year, and 10-year, are also calculated to provide information on how likely one stage moves to another stage within a specific time period.
Introduction
The Markov (1906) chain model has been applied in various fields such as physics, queuing theory, internet application, economics, finance, and social sciences among others. As an effective and efficient way of describing a process in which an individual moves through a series of states (stages) in continuous time, homogeneous Markov models have also been extensively used in health sciences where the progression of certain diseases are of great importance to both doctors and patients. In the present study, the main objective is to investigate the progression of breast cancer in Chunling Cong is a doctoral student in Statistics at the University of South Florida. Her research interests are in developing forecasting and statistical analysis and modeling of cancer. Email: ccong@mail.usf.edu. Chris Tsokos is a Distinguished University Professor in mathematics and Statistics at the University of South Florida. His research interests are in modeling Global Warming, analysis and modeling of cancer data, parametric, Bayesian and nonparametric reliability, and stochastic systems, among others. He is a fellow of both ASA and ISI. Email: profcpt@cas.usf.edu. patients in three different stages who were given different treatments. One group of patients received combined treatments of tamoxifen and radiation, and the other group received only tamoxifen. Figure 1 shows the three stages of interest in the study are: alive with no relapse, alive with relapse, and deceased. Even though breast cancer patients who have recurrence may be treated and recover from breast cancer to become active with no relapse, due to the fact that the data does not include any observations of that process, we consider the second statealive with relapse as those patients who once had relapse and are still alive, regardless of whether they have recovered from breast cancer or not.
Methodology
Between December 1992 and June 2000, a total of 769 women were enrolled and randomized in the study. Among these, 386 received combined radiation and tamoxifen (RT+Tam), and the between the stages at different times satisfy the Markov property: the conditional probability of future one-step-event conditioned on the entire past of the process is just conditioned on the present stage of the process. In other words, the one-step future stage depends only on the present stage: 
, (3) where h is the time interval. 
where probabilities in each row add up to 1. Thus, it is 100% certain that for any individual at time t is in one of the stages and the sum of probabilities of being in each stage is 1. The transition probability matrix can be calculated by taking the matrix exponential of the scaled transition intensity matrix defined by 
Scenario 2 If the exact times of transitions between different stages are recorded and there is no transition between the observation times, the contribution to the likelihood from this pair of stages is: 
Results The breast cancer patients were divided into two groups RT+Tam and Tam based on the different treatments they received. For those patients who received combined treatments, 26 patients experienced relapse, 13 patients died without recurrence of breast cancer during the entire period of the study, and 14 died after recurrence of breast cancer. For the patients in the Tam group, 51 patients experienced relapse, 10 died without reoccurrence of breast cancer, and 13 died after recurrence of breast cancer.
As can be observed from the transition intensity matrixes for both groups RT+Tam and Tam as shown in Tables 1 and 2 , patients who received single treatment have a higher transition intensity form Stage 1 to Stage 2, thus, they are more likely to have breast cancer recurrence. Thus, the probability of that happening in the Tam group is higher than that of the RT+Tam group. For those patients who died without relapse, there is no significant difference between the two treatments as illustrated by the intensity form Stage 1 to Stage 3.
Combined treatment is also more effective than a single treatment with respect to the possibility of death without relapse as can be observed from the transition intensity from Stage 1 to Stage 3. However, for those who already experienced relapse of breast cancer, patients who received combined treatments are more likely to die than those who received a single treatment. Therefore, combined treatment should be chosen over single treatment to avoid recurrence, but for those patients who already had breast cancer relapse, it would be advisable to choose a single treatment to extend the time from recurrence to death.
Figures 3 and 4 illustrate the effectiveness of the two treatments with respect to the survival probabilities and also show the survival curves of the patients who had recurrence and who had no recurrence in each treatment group.
From the above analysis, the proposed Markov chain model provides recommendations for which treatment to choose for breast cancer patients with respect to relapse and survival time. Moreover, it provides patients with very important information on the exact time or possibilities of recurrence and death. Estimated mean sojourn times in each transient stage for patients who received combined treatment are 43.46 and 3.25 in Stage 1 and Stage 2, respectively. Estimated mean sojourn times for patients who received single treatment are 25.53 and 11.72 in Stage 1 and Stage 2. This further confirms that patients with combined treatment will remain in Stage 1 longer than those with single treatment; however, for patients who had relapse of breast cancer, patients with single treatment will stay alive longer than those with combined treatment.
Another goal of this study was to provide a transition probability matrix at different times so that given a specific time period, the probability that a patient in a given stage will transit to another stage could be conveyed. Tables 5a-8b give 2-year, 4-year, 5-year and 10-year transition probability matrixes of patients in RT+Tam and Tam.
Conclusion
Through Markov chain modeling of the three stages of breast cancer patients , it has been shown that combined treatment of tamoxifen and radiation is more effective than single treatment of tamoxifen in preventing the recurrence of breast cancer. However, for patients who had a relapse of breast cancer, single treatment of tamoxifen proves to be more effective than combined treatment with respect to the survival probability. This finding could give significant guidance to doctors with respect to which breast cancer treatment should be given to breast cancer patients in different stages. Transition probabilities between different stages during 2 years, 4 years, 5 years and 10 years are also calculated for predicting purposes. 
